Brief: Voyager Therapeutics Reports Robust Preclinical Activity In TAU Silencing Gene Therapy Program For Alzheimer’S And Advances Program Into Late Research
20/02/2024 12:15
Feb 20 (Reuters) - Voyager Therapeutics Inc VYGR.O :
* VOYAGER THERAPEUTICS REPORTS ROBUST PRECLINICAL ACTIVITY
IN TAU
SILENCING GENE THERAPY PROGRAM FOR ALZHEIMER’S DISEASE AND
ADVANCES PROGRAM INTO LATE RESEARCH
Source text for Eikon: ID:nGNX56y9Yc
Further company coverage: VYGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview